Funder
Department of Health Research
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Ferlay J, Laversanne M, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020) Global Cancer Observatory: Cancer Tomorrow. International Agency for Research on Cancer, Lyon, France
2. Yoneda A, Lendorf ME, Couchman JR, Multhaupt HA (2012) Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans. J Histochem Cytochem 60(1):9–21
3. Gajjar K, Ogden G, Mujahid MI, Razvi K (2012) Symptoms and risk factors of ovarian cancer: a survey in primary care. ISRN Obstet Gynecol. 2012:754197
4. NCCN Clinical Practice Guidelines in Oncology™. Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer. V.1.2016. Available at: http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed March 18 2018
5. Friedlander M, Gebski V, Gibbs E, Davies L, Bloomfield R, Hilpert F, Wenzel LB, Eek D, Rodrigues M, Clamp A, Penson RT, Provencher D, Korach J, Huzarski T, Vidal L, Salutari V, Scott C, Nicoletto MO, Tamura K, Espinoza D, Joly F, Pujade-Lauraine E (2018) Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncol 19(8):1126–1134. https://doi.org/10.1016/S1470-2045(18)30343-7
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献